Previous Mistakes with DCB Technology, and How to Prevent Them in the Future

  • Dario Buccheri
  • Bernardo Cortese


Drug-coated balloon (DCB) is a relatively novel device for coronary and peripheral artery disease management [1]. It consists in a conventional balloon angioplasty covered by an antiproliferative drug. This technology allows to bring high concentration of an antiproliferative drug with rapid local delivery without the implantation of an external prosthesis like a metal stent or a scaffold, technologies associated with some late-occurring thrombotic events. In this light, the shorter dual antiplatelet therapy (DAPT) duration usually required with DCB may be an advantage because it warrants a reduced bleeding risk, especially in high-risk and compromised patients.


  1. 1.
    Cortese B, Granada JF, Scheller B, et al. Drug-coated balloon treatment for lower extremity vascular disease intervention: an international positioning document. Eur Heart J. 2016;37:1096–103.CrossRefGoogle Scholar
  2. 2.
    Cortese B, Berti S, Biondi-Zoccai G, et al. Drug-coated balloon treatment of coronary artery disease: a position paper of the Italian Society of Interventional Cardiology. Catheter Cardiovasc Interv. 2014;83:427–35.CrossRefGoogle Scholar
  3. 3.
    Cortese B, Bertoletti A. Paclitaxel coated balloons for coronary artery interventions: a comprehensive review of preclinical and clinical data. Int J Cardiol. 2012;161:4–12.CrossRefGoogle Scholar
  4. 4.
    Kaule S, Minrath I, Stein F, et al. Correlating coating characteristics with the performance of drug-coated balloons – a comparative in vitro investigation of own established hydrogel- and ionic liquid-based coating matrices. PLoS One. 2015;10:e0116080.CrossRefGoogle Scholar
  5. 5.
    Cortese B, Micheli A, Picchi A, Coppolaro A, Bandinelli L, Severi S, Limbruno U. Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO study. Heart. 2010;96:1291–6.CrossRefGoogle Scholar
  6. 6.
    Kufner S, Joner M, Schneider S, Tölg R, Zrenner B, Repp J, Starkmann A, Xhepa E, Ibrahim T, Cassese S, Fusaro M, Ott I, Hengstenberg C, Schunkert H, Abdel-Wahab M, Laugwitz KL, Kastrati A, Byrne RA, ISAR-DESIRE 4 Investigators. Neointimal modification with scoring balloon and efficacy of drug-coated balloon therapy in patients with restenosis in drug-eluting coronary stents: a randomized controlled trial. JACC Cardiovasc Interv. 2017;10:1332–40.CrossRefGoogle Scholar
  7. 7.
    Kleber FX, Mathey DG, Rittger H, Scheller B, German Drug-eluting Balloon Consensus Group. How to use the drug-eluting balloon: recommendations by the German consensus group. EuroIntervention. 2011;7(Suppl K):K125–8.CrossRefGoogle Scholar
  8. 8.
    Unverdorben M, Kleber FX, Heuer H, Figulla HR, Vallbracht C, Leschke M, Cremers B, Hardt S, Buerke M, Ackermann H, Boxberger M, Degenhardt R, Scheller B. Treatment of small coronary arteries with a paclitaxel-coated balloon catheter. Clin Res Cardiol. 2010;99:165–74.CrossRefGoogle Scholar
  9. 9.
    Mitomo S, Mangieri A, Regazzoli D, Ancona M, Giannini F, Chieffo A, Montorfano M, Latib A, Colombo A. TCT-526 mid-term clinical outcomes after bailout stenting with drug-eluting stent for suboptimal results of drug-coated balloon; Milan registry. J Am Coll Cardiol. 2017;70(18 Supplement):B218. Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Dario Buccheri
    • 1
  • Bernardo Cortese
    • 2
  1. 1.Interventional CardiologyTrapani HospitalTrapaniItaly
  2. 2.Cardiac DepartmentSan Carlo ClinicMilanoItaly

Personalised recommendations